BidaskClub lowered shares of Immunomedics, Inc. (NASDAQ:IMMU) from a strong-buy rating to a buy rating in a research report released on Tuesday morning.

IMMU has been the topic of several other research reports. Cowen and Company restated an outperform rating and issued a $15.00 target price on shares of Immunomedics in a research note on Monday, July 24th. Zacks Investment Research upgraded shares of Immunomedics from a sell rating to a buy rating and set a $9.50 target price on the stock in a research note on Tuesday, July 11th. Wells Fargo & Company raised Immunomedics from a market perform rating to an outperform rating in a report on Friday, May 5th. Jefferies Group LLC reaffirmed a buy rating and issued a $11.00 price target on shares of Immunomedics in a report on Friday, July 14th. Finally, ValuEngine raised Immunomedics from a sell rating to a hold rating in a report on Friday, June 2nd. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The company currently has an average rating of Buy and a consensus price target of $12.00.

Immunomedics (NASDAQ IMMU) traded up 2.34% during mid-day trading on Tuesday, hitting $8.75. 1,955,596 shares of the company were exchanged. Immunomedics has a 12-month low of $2.02 and a 12-month high of $9.51. The company’s market cap is $959.04 million. The stock’s 50 day moving average is $8.53 and its 200-day moving average is $6.51.

COPYRIGHT VIOLATION NOTICE: This report was posted by Watch List News and is the property of of Watch List News. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The original version of this report can be accessed at https://www.watchlistnews.com/immunomedics-inc-immu-downgraded-by-bidaskclub-to-buy/1461802.html.

A number of hedge funds have recently made changes to their positions in the company. Spark Investment Management LLC purchased a new stake in shares of Immunomedics during the second quarter valued at $723,000. Creative Planning boosted its stake in shares of Immunomedics by 1.7% in the second quarter. Creative Planning now owns 179,130 shares of the biopharmaceutical company’s stock valued at $1,582,000 after buying an additional 3,065 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Immunomedics by 177.8% in the first quarter. Goldman Sachs Group Inc. now owns 417,079 shares of the biopharmaceutical company’s stock valued at $2,699,000 after buying an additional 266,953 shares in the last quarter. Point72 Asset Management L.P. boosted its stake in shares of Immunomedics by 1,648.0% in the first quarter. Point72 Asset Management L.P. now owns 1,195,613 shares of the biopharmaceutical company’s stock valued at $7,736,000 after buying an additional 1,127,213 shares in the last quarter. Finally, HighTower Advisors LLC boosted its stake in shares of Immunomedics by 13.8% in the first quarter. HighTower Advisors LLC now owns 58,115 shares of the biopharmaceutical company’s stock valued at $375,000 after buying an additional 7,050 shares in the last quarter. 62.02% of the stock is owned by hedge funds and other institutional investors.

Immunomedics Company Profile

Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.

Receive News & Ratings for Immunomedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.